637 related articles for article (PubMed ID: 35163300)
1. Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover.
Cheng CH; Chen LR; Chen KH
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163300
[TBL] [Abstract][Full Text] [Related]
2. Hormone-Related and Drug-Induced Osteoporosis: A Cellular and Molecular Overview.
Wang LT; Chen LR; Chen KH
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982891
[TBL] [Abstract][Full Text] [Related]
3. Ablation of p38α MAPK Signaling in Osteoblast Lineage Cells Protects Mice From Bone Loss Induced by Estrogen Deficiency.
Thouverey C; Caverzasio J
Endocrinology; 2015 Dec; 156(12):4377-87. PubMed ID: 26441240
[TBL] [Abstract][Full Text] [Related]
4. A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice.
Kalyanaraman H; Ramdani G; Joshua J; Schall N; Boss GR; Cory E; Sah RL; Casteel DE; Pilz RB
J Bone Miner Res; 2017 Jan; 32(1):46-59. PubMed ID: 27391172
[TBL] [Abstract][Full Text] [Related]
5. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
6. Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes.
Allison H; Holdsworth G; McNamara LM
BMC Mol Cell Biol; 2020 Nov; 21(1):78. PubMed ID: 33148174
[TBL] [Abstract][Full Text] [Related]
7. A Novel Rhein Derivative Modulates Bone Formation and Resorption and Ameliorates Estrogen-Dependent Bone Loss.
Jiang M; Wang T; Yan X; Liu Z; Yan Y; Yang K; Qi J; Zhou H; Qian N; Zhou Q; Chen B; Xu X; Xi X; Yang C; Deng L
J Bone Miner Res; 2019 Feb; 34(2):361-374. PubMed ID: 30320929
[TBL] [Abstract][Full Text] [Related]
8. Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption.
Kitaura H; Marahleh A; Ohori F; Noguchi T; Shen WR; Qi J; Nara Y; Pramusita A; Kinjo R; Mizoguchi I
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708317
[TBL] [Abstract][Full Text] [Related]
9. Pro-inflammatory Cytokines: Cellular and Molecular Drug Targets for Glucocorticoid-induced-osteoporosis via Osteocyte.
Wang T; Yu X; He C
Curr Drug Targets; 2019; 20(1):1-15. PubMed ID: 29618305
[TBL] [Abstract][Full Text] [Related]
10. IL-6, IL-1β, and TNF-α only in combination influence the osteoporotic phenotype in Crohn's patients via bone formation and bone resorption.
Blaschke M; Koepp R; Cortis J; Komrakova M; Schieker M; Hempel U; Siggelkow H
Adv Clin Exp Med; 2018 Jan; 27(1):45-56. PubMed ID: 29521042
[TBL] [Abstract][Full Text] [Related]
11. [Action of glucocorticoid on bone-forming and bone-resorbing cells].
Hakeda Y
Clin Calcium; 2006 Nov; 16(11):1817-22. PubMed ID: 17079848
[TBL] [Abstract][Full Text] [Related]
12. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
13. Insights into the antiosteoporotic mechanism of the soy-derived isoflavone genistein: Modulation of the Wnt/beta-catenin signaling.
Mannino F; Imbesi C; Irrera N; Pallio G; Squadrito F; Bitto A
Biofactors; 2024; 50(2):347-359. PubMed ID: 37767998
[TBL] [Abstract][Full Text] [Related]
14. TNF-α promotes osteoclastogenesis through JNK signaling-dependent induction of Semaphorin3D expression in estrogen-deficiency induced osteoporosis.
Sang C; Zhang J; Zhang Y; Chen F; Cao X; Guo L
J Cell Physiol; 2017 Dec; 232(12):3396-3408. PubMed ID: 28059444
[TBL] [Abstract][Full Text] [Related]
15. IGFBP7 acts as a negative regulator of RANKL-induced osteoclastogenesis and oestrogen deficiency-induced bone loss.
Ye C; Hou W; Chen M; Lu J; Chen E; Tang L; Hang K; Ding Q; Li Y; Zhang W; He R
Cell Prolif; 2020 Feb; 53(2):e12752. PubMed ID: 31889368
[TBL] [Abstract][Full Text] [Related]
16. Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice.
Piemontese M; Xiong J; Fujiwara Y; Thostenson JD; O'Brien CA
Am J Physiol Endocrinol Metab; 2016 Sep; 311(3):E587-93. PubMed ID: 27460899
[TBL] [Abstract][Full Text] [Related]
17. Eicosapentaenoic acid supplementation modulates the osteoblast/osteoclast balance in inflammatory environments and protects against estrogen deficiency-induced bone loss in mice.
Wang Z; Wu J; Li L; Wang K; Wu X; Chen H; Shi J; Zhou C; Zhang W; Hang K; Xue D; Pan Z
Clin Nutr; 2023 Sep; 42(9):1715-1727. PubMed ID: 37542949
[TBL] [Abstract][Full Text] [Related]
18. Interaction between bone and immune cells: Implications for postmenopausal osteoporosis.
Fischer V; Haffner-Luntzer M
Semin Cell Dev Biol; 2022 Mar; 123():14-21. PubMed ID: 34024716
[TBL] [Abstract][Full Text] [Related]
19. LIGHT/TNFSF14 regulates estrogen deficiency-induced bone loss.
Brunetti G; Storlino G; Oranger A; Colaianni G; Faienza MF; Ingravallo G; Di Comite M; Reseland JE; Celi M; Tarantino U; Passeri G; Ware CF; Grano M; Colucci S
J Pathol; 2020 Apr; 250(4):440-451. PubMed ID: 31990039
[TBL] [Abstract][Full Text] [Related]
20. The molecular etiology and treatment of glucocorticoid-induced osteoporosis.
Peng CH; Lin WY; Yeh KT; Chen IH; Wu WT; Lin MD
Tzu Chi Med J; 2021; 33(3):212-223. PubMed ID: 34386357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
